首页> 外文OA文献 >Recurrence of Urothelial Carcinoma of the Bladder: A Role for Insulin-Like Growth Factor-II Loss of Imprinting and Cytoplasmic E-Cadherin Immunolocalization
【2h】

Recurrence of Urothelial Carcinoma of the Bladder: A Role for Insulin-Like Growth Factor-II Loss of Imprinting and Cytoplasmic E-Cadherin Immunolocalization

机译:膀胱尿路上皮癌的复发:胰岛素样生长因子-II印迹和细胞质E-钙黏着蛋白免疫定位的损失。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose:This study documents the frequency of insulin-like growth factor-II (IGF-II) loss of imprinting (LOI) in a series of 87 bladder tissues. E-cadherin (CDH1) immunolocalization was also investigated due to the known redistribution of this adherence protein to the cytoplasm following exogenous exposure to IGF-II.Experimental Design: Informative IGF-II cases were identified following DNA-PCR amplification and subsequent sequencing of the transcribable ApaI RFLP in exon 9 of IGF-II. Similar approaches using primer-specific cDNA templates identified the imprinting status of IGF-II in these informative cases. CDH1cellular localization was assessed on a tissue microarray platform of 114 urothelial carcinoma of the bladder (UCB) cases (70 pTanoninvasive and 44 pT1laminapropria invasive) using the commercially available Novocastra antibody.Results: IGF-IILOI was evident in 7 of17 (41%) UCB tumors and 4 of11 (36%) tumor-associated normal urothelial samples.Two of four pT1grade 3 tumors, the subject of much debate concerning their suitability for radical cystectomy, showed LOI at the IGF-II locus. In those tumors showing IGF-II LOI, 4 of 7 (57%) displayed concomitant CDH1cytoplasmic staining. In contrast, only 3 of 10 (30%) IGF-IImaintenance ofimprinting tumorshad concomitant CDH1cytoplasmiclocalization. UCB cell lines displaying cytoplasmic CDH1immunolocalization expressed significantly higher levels of IGF-II (CAL29, HT1376, and RT112) compared with RT4, a cell line displaying crisp membranous CDH1staining. Finally, cytoplasmic CDH1staining was an independent predictor of a shorter time to recurrence independent of tumor grade and stage.Conclusions: We suggest that CDH1 cytoplasmic immunolocalization as a result of increased IGF-II levels identifies those nonmuscle invasive presentations most likely to recur and therefore might benefit from more radical nonconserving bladder surgery
机译:目的:本研究记录了一系列87个膀胱组织中胰岛素样生长因子-II(IGF-II)印迹(LOI)丢失的频率。 E-钙粘蛋白(CDH1)的免疫定位也进行了研究,因为这种粘附蛋白在外源暴露于IGF-II后会重新分布到细胞质中。实验设计:信息性IGF-II病例是通过DNA-PCR扩增和随后测序确定的IGF-II外显子9中的可转录ApaI RFLP。在这些资料丰富的案例中,使用引物特异性cDNA模板的类似方法确定了IGF-II的印迹状态。使用市售的Novocastra抗体,在114例膀胱​​尿路上皮癌(UCB)病例(70 pTanon浸润和44 pT1 lamproppropproper浸润)的组织微阵列平台上评估了CDH1细胞的定位。结果:IGF-IILOI在17例UCB中有7例(41%)明显肿瘤和11个肿瘤中的4个(36%)与肿瘤相关的正常尿道上皮样品.4个pT1级3个肿瘤中有2个关于其是否适合行根治性膀胱切除术争论不休,在IGF-II位点显示LOI。在那些表现出IGF-II LOI的肿瘤中,有7个中有4个(57%)伴有CDH1细胞质染色。相比之下,印有肿瘤的10个IGF-II维护中只有3个(30%)伴有CDH1细胞质定位。与RT4相比,显示胞质CDH1免疫定位的UCB细胞系表达的IGF-II(CAL29,HT1376和RT112)水平显着更高,RT4显示膜状CDH1染色较脆。最后,胞浆CDH1染色是一个较短的复发时间的独立预测因子,与肿瘤的分级和分期无关。结论:我们认为,由于IGF-II水平升高,CDH1胞浆的免疫定位可以确定那些最有可能复发的非肌肉浸润性表现,因此可能受益于更彻底的非保守性膀胱手术

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号